05.05.23
OBiO Technology Corp., a provider of gene and cell therapy-focused biotechnology, entered into a strategic commercial manufacturing collaboration with Chinagene, a developer of clinical genetic diagnosis, and gene therapy drugs.
Under the agreement, OBiO will provide contract development and manufacturing services to Chinagene for their gene therapy products, including large-scale cGMP manufacturing service for clinical trials, process characterization and validation services, product formulation and filling services, and commercial manufacturing.
In addition, OBiO and Chinagene will continue to expand the cooperation in academic communication globally, to promote the innovation of gene therapy.
"This agreement signed by OBiO and Chinagene is a continuation and sublimation from previous cooperation," said, Guodong Jia, CEO of OBiO. " Chinagene is a leading biotech among the ophthalmic gene therapy developer. OBiO is a leading gene and cell therapy CDMO in China. OBiO will continue to improve the capability of process development and cGMP management system, to promote the gene therapy product of Chinagene."
Xi Chen, vice president of Chinagene said, "OBiO has abundant experience in gene therapy manufacturing and cGMP quality, management. We are happy to continue our collaboration to accelerate the commercialization of our ophthalmic gene therapy product ZVS101e." "In past, OBiO had helped us to get the investigational new drug (IND) approvals from National Medical Products Administration of China (NMPA) and the U.S. Food and Drug Administration (FDA). In future, we will continue to work closely with our own abilities, to help more patients."
Under the agreement, OBiO will provide contract development and manufacturing services to Chinagene for their gene therapy products, including large-scale cGMP manufacturing service for clinical trials, process characterization and validation services, product formulation and filling services, and commercial manufacturing.
In addition, OBiO and Chinagene will continue to expand the cooperation in academic communication globally, to promote the innovation of gene therapy.
"This agreement signed by OBiO and Chinagene is a continuation and sublimation from previous cooperation," said, Guodong Jia, CEO of OBiO. " Chinagene is a leading biotech among the ophthalmic gene therapy developer. OBiO is a leading gene and cell therapy CDMO in China. OBiO will continue to improve the capability of process development and cGMP management system, to promote the gene therapy product of Chinagene."
Xi Chen, vice president of Chinagene said, "OBiO has abundant experience in gene therapy manufacturing and cGMP quality, management. We are happy to continue our collaboration to accelerate the commercialization of our ophthalmic gene therapy product ZVS101e." "In past, OBiO had helped us to get the investigational new drug (IND) approvals from National Medical Products Administration of China (NMPA) and the U.S. Food and Drug Administration (FDA). In future, we will continue to work closely with our own abilities, to help more patients."